Literature DB >> 17314058

Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR.

Giselle Fernandes Taboada1, Lívia Lugarinho Correa, Evelyn de Oliveira Machado, Flávia Regina van Haute, Alessandra Ferri Casini, Giovanna Aparecida Balarini, Leonardo Vieira Neto, Lilia Calixto, Cláudia Calixto, Mônica Roberto Gadelha.   

Abstract

BACKGROUND: GH secretion, in acromegaly, is characterized by increased basal levels, as well as by increased frequency and amplitude of pulses. Evaluation of disease activity during follow-up of treated patients is frequently done with mean GH levels, although there is no established protocol for sample collection.
OBJECTIVE: Determine mean GH value of 5 blood samples collected 30 min apart for 2 consecutive hours in the follow-up of acromegalic patients treated with octreotide LAR.
METHODS: Ninety-one GH curves of 44 patients (25 women) were evaluated as were the respective IGF-I values (basal). Normal IGF-I for age and sex was considered standard for control of disease activity. Correlations between basal and mean GH were studied as were correlations between both values and %IGF-I above the upper limit of reference values (%ULRV).
RESULTS: Median age of the group was 45.5 years (range 28-73). Twenty-five patients (56.8%) had previous surgery and 7 (15.9%) had both surgery and radiotherapy. A positive correlation was found between mean and basal GH (r=0.953; p<0.001). Both basal and mean GH were correlated to %ULRV (r=0.645 and 0.661; p<0.001 for both). In only 3 of the 91 curves (3.3%) there were discordances between basal GH and IGF-I, however the latter was concordant with mean GH. In 3 other curves there was concordance between basal GH and IGF-I although the latter was discordant with mean GH.
CONCLUSIONS: There was no benefit to perform GH curves with the present protocol. It may be due to our established outpatient follow up protocol. The use of more complex protocols and the cost of multiple GH assays should be acknowledged, and probably reserved for patients with basal GH levels between 1 and 5 microg/L with discordant GH and IGF-I.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314058     DOI: 10.1016/j.ghir.2006.12.003

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  3 in total

1.  Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.

Authors:  M Scacchi; C Carzaniga; G Vitale; L M Fatti; F Pecori Giraldi; M Andrioli; A Cattaneo; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

2.  Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models.

Authors:  Katica Bajuk Studen; Ariel Barkan
Journal:  J Clin Endocrinol Metab       Date:  2007-11-20       Impact factor: 5.958

3.  Mean GH profile is more accurate than single fasting GH in the evaluation of acromegaly disease control during somatostatin receptor ligands therapy.

Authors:  C Bona; N Prencipe; A M Berton; F Bioletto; M Parasiliti-Caprino; V Gasco; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2022-06-24       Impact factor: 5.467

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.